Hepatitis B vaccine adverse events in China: Risk control and regulation

The death of 17 children raised public fears over infant hepatitis B vaccination in China. Though the relation between hepatitis B and children's death was denied after prudent investigation, the negative impact remained. In order to prevent or minimize adverse events after vaccination, special...

Descripción completa

Detalles Bibliográficos
Autores principales: Meina, Li, Xiaodong, Liu, Lulu, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443087/
https://www.ncbi.nlm.nih.gov/pubmed/25483642
http://dx.doi.org/10.4161/21645515.2014.971643
_version_ 1783238517970698240
author Meina, Li
Xiaodong, Liu
Lulu, Zhang
author_facet Meina, Li
Xiaodong, Liu
Lulu, Zhang
author_sort Meina, Li
collection PubMed
description The death of 17 children raised public fears over infant hepatitis B vaccination in China. Though the relation between hepatitis B and children's death was denied after prudent investigation, the negative impact remained. In order to prevent or minimize adverse events after vaccination, special strategy including regulation and reimbursement should be developed.
format Online
Article
Text
id pubmed-5443087
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-54430872017-06-01 Hepatitis B vaccine adverse events in China: Risk control and regulation Meina, Li Xiaodong, Liu Lulu, Zhang Hum Vaccin Immunother Commentary The death of 17 children raised public fears over infant hepatitis B vaccination in China. Though the relation between hepatitis B and children's death was denied after prudent investigation, the negative impact remained. In order to prevent or minimize adverse events after vaccination, special strategy including regulation and reimbursement should be developed. Taylor & Francis 2014-10-31 /pmc/articles/PMC5443087/ /pubmed/25483642 http://dx.doi.org/10.4161/21645515.2014.971643 Text en © 2014 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentary
Meina, Li
Xiaodong, Liu
Lulu, Zhang
Hepatitis B vaccine adverse events in China: Risk control and regulation
title Hepatitis B vaccine adverse events in China: Risk control and regulation
title_full Hepatitis B vaccine adverse events in China: Risk control and regulation
title_fullStr Hepatitis B vaccine adverse events in China: Risk control and regulation
title_full_unstemmed Hepatitis B vaccine adverse events in China: Risk control and regulation
title_short Hepatitis B vaccine adverse events in China: Risk control and regulation
title_sort hepatitis b vaccine adverse events in china: risk control and regulation
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443087/
https://www.ncbi.nlm.nih.gov/pubmed/25483642
http://dx.doi.org/10.4161/21645515.2014.971643
work_keys_str_mv AT meinali hepatitisbvaccineadverseeventsinchinariskcontrolandregulation
AT xiaodongliu hepatitisbvaccineadverseeventsinchinariskcontrolandregulation
AT luluzhang hepatitisbvaccineadverseeventsinchinariskcontrolandregulation

Ejemplares similares